Updates are available Correction dated 2022-12-22
Click to view Correction: https://doi.org/10.1186/s12885-022-10455-0
-
Authors
Allahyari, Abolghasem
Ehsanpour, Ali
Najafi, Behrouz
Ansarinejad, Nafiseh
Mehrzad, Valiollah
Kalantari, Behjat
Raafat, Jahangir
Ghadiany, Mojtaba
Shahi, Farhad
Gharib, Behrooz
Moazed, Vahid
Khosravi, Adnan
Mirpour, Mir Hossein
Salari, Sina
Mortazavizadeh, Seyedmohammadreza
Nekoyi, Amirabbas
Khani, Mohsen
Sadeghi, Alireza
Gharib, Sirus
Bary, Alireza
Mirzania, Mehrzad
Haghighat, Shirin
Razavi, Seyed Mohsen
Emami, Seyed Amir Hossein
Hosseinzadeh, Mehran
Mirbolouk, Mahdi
Sadighi, Sanambar
Shahrasbi, Abdolali
Esfahani, Ali
Gity, Masoumeh
Anjidani, Nassim
Kafi, Hamidreza
Najafi, Safa
- License Information
-
More Information
Article History
Received: 2 November 2021
Accepted: 14 July 2022
First Online: 7 September 2022
Change Date: 22 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-022-10455-0
Declarations
:
: The study was performed in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki.Each participant signed a written informed-consent form before the initiation of the trial.Research Ethics Committee of Tehran University of Medical Sciences: (IR.TUMS.VCR.REC.1397.127).Research Ethics Committee of Guilan University of Medical Sciences: (IR.GUMS.REC.1395.444).Clinicaltrials.gov registration code: (NCT04957212) - First registered on 12/07/2021.Iranian Registry of Clinical Trials (IRCT) registration code: IRCT20150303021315N11 - First registered on 11/06/2018.
: Not applicable.
: Nassim Anjidani is the head of the medical department of Orchid Pharmed Company, which is in collaboration with CinnaGen Company with respect to conducting clinical trials. Hamidreza Kafi is head of advisory board in Orchid Pharmed Company. No other potential conflicts of interest relevant to this article were reported.
